Darolutamide improves metastasis-free survival in nonmetastatic, castration-resistant prostate cancer
Among men with nonmetastatic, castration-resistant prostate cancer, metastasis-free survival was significantly longer with darolutamide, androgen-receptor antagonist than with placebo. The incidence of adverse events was similar for darolutamide and placebo. These findings are published Feb. 14, 2019 in the New England Journal of Medicine.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies